Table 3 Pharmacological treatments and radiotherapy in HER2 positive Breast Cancer Patients
n (%) | |
|---|---|
Pharmacological treatment setting from diagnosis till end of data collection (cut-off point), n = 309 | |
Neoadjuvant only | 10 (3.2%) |
Adjuvant only | 134 (43.4%) |
Metastatic only | 46 (14.9%) |
Neoadjuvant + Adjuvant + Metastatic | 22 (7.1%) |
Neoadjuvant + Adjuvant | 74 (23.9%) |
Adjuvant + Metastatic | 19 (6.1%) |
Neoadjuvant treatment regimens, n = 110 | |
Neoadjuvant + Metastatic | 4 (1.3%) |
Hormonotherapy alone | 3 (2.7%) |
Chemotherapy alone | 83 (75.5%) |
Trastuzumab alone | 7 (6.4%) |
Chemotherapy + Trastuzumab | 87 (79.1%) |
Other regimens | 2 (1.8%) |
Adjuvant treatment regimens, n = 249 | |
Hormonotherapy alone | 140 (56.2%) |
Chemotherapy alone | 113 (45.4%) |
Trastuzumab alone | 96 (38.6%) |
Chemotherapy + Trastuzumab | 129 (51.8%) |
Hormonotherapy + Trastuzumab | 22 (8.8%) |
Metastatic treatment regimens, n = 91 | |
Hormonotherapy alone | 41 (45.1%) |
Chemotherapy alone | 40 (44.0%) |
Targeted therapy alone | 36 (45.1%) |
Chemotherapy + Targeted therapy | 59 (64.8%) |
Hormonotherapy + Targeted therapy | 14 (15.4%) |
Hormonotherapy + Chemotherapy + Targeted therapy | 2 (3.3%) |
Radiotherapy, n = 347 | |
No | 98 (28.2%) |
Yes | 249 (71.8%) |